Hosted on MSN
LEXX: IRB Approval Clears Way for GLP-1 Study #5
Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 results along with program updates, progress in its GLP-1 trials, a capital raise and final preparations for the Phase ...
Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal second quarter 2024 results along with program updates, progress in its GLP-1 and hypertension trials, a capital raise and appointment of a ...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug-delivery platforms, is partnering with a contract research organization (“CRO”) to conduct its human pilot study #3. According to ...
Kelowna, British Columbia – TheNewswire - November 25, 2024 – Lexaria Bioscience Corp. (Nasdaq: LEXX, LEXXW) (the “Company” or “Lexaria”), a global ...
Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced it has hired a contract research organization (“CRO”) to perform the company’s second ...
(MENAFN- Investor Brand Network) Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced that its second human pilot study, GLP-1-H24-2, is underway ...
(MENAFN- Investor Brand Network) Lexaria Bioscience (NASDAQ: LEXX, LEXXW) , a global innovator in drug delivery platforms, today announced it has hired a contract research organization (“CRO”) to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results